ATE319743T1 - Zusammensetzungen auf der basis von gfr-alpha-4 und deren anwendungen - Google Patents

Zusammensetzungen auf der basis von gfr-alpha-4 und deren anwendungen

Info

Publication number
ATE319743T1
ATE319743T1 AT00977623T AT00977623T ATE319743T1 AT E319743 T1 ATE319743 T1 AT E319743T1 AT 00977623 T AT00977623 T AT 00977623T AT 00977623 T AT00977623 T AT 00977623T AT E319743 T1 ATE319743 T1 AT E319743T1
Authority
AT
Austria
Prior art keywords
seq
polypeptides
present
gfralpha4
mammalian
Prior art date
Application number
AT00977623T
Other languages
English (en)
Inventor
Matti Airaksinen
Mart Saarma
Dimitri Friedrich-Mi Poteriaev
Maria Lindahl
Toenis Timmusk
Jari Rossi
Original Assignee
Licentia Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Licentia Ltd filed Critical Licentia Ltd
Application granted granted Critical
Publication of ATE319743T1 publication Critical patent/ATE319743T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Steroid Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
AT00977623T 2000-02-21 2000-11-14 Zusammensetzungen auf der basis von gfr-alpha-4 und deren anwendungen ATE319743T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FI20000394A FI20000394A0 (fi) 2000-02-21 2000-02-21 GFRa4:n sukuisia tai siitä johdettuja aineita sekä niiden käyttö

Publications (1)

Publication Number Publication Date
ATE319743T1 true ATE319743T1 (de) 2006-03-15

Family

ID=8557643

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00977623T ATE319743T1 (de) 2000-02-21 2000-11-14 Zusammensetzungen auf der basis von gfr-alpha-4 und deren anwendungen

Country Status (9)

Country Link
US (1) US7488588B1 (de)
EP (1) EP1257581B1 (de)
JP (1) JP2003523762A (de)
AT (1) ATE319743T1 (de)
AU (1) AU782897B2 (de)
CA (1) CA2397705A1 (de)
DE (1) DE60026569T2 (de)
FI (1) FI20000394A0 (de)
WO (1) WO2001062795A1 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2958200A1 (en) 2014-08-14 2016-02-18 Novartis Ag Treatment of cancer using a gfr alpha-4 chimeric antigen receptor
WO2016025884A1 (en) * 2014-08-14 2016-02-18 The Trustees Of The University Of Pennsylvania Glycosyl-phosphatidylinositol (gpi)-linked gdnf family alpha-receptor 4 (gfralpha4)-specific antibody and uses thereof
EP4041404A4 (de) 2019-09-30 2023-10-25 The Trustees of the University of Pennsylvania Humanisierte anti-gdnf-familie alpha-rezeptor 4 (grf-alpha-4) antikörper und chimäre antigen-rezeptoren (cars)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6455277B1 (en) * 1996-04-22 2002-09-24 Amgen Inc. Polynucleotides encoding human glial cell line-derived neurotrophic factor receptor polypeptides
WO1999050298A1 (en) 1998-03-31 1999-10-07 Millennium Pharmaceuticals, Inc. GFRα-X, A NOVEL GLIAL-DERIVED NEUROTROPHIC FACTOR RECEPTOR AND USES THEREFOR
FI981217A7 (fi) * 1998-05-29 1999-11-30 Matti S Airaksinen GFRalfa2 negatiiviset hiiret toimivat kokeellisina malleina eräille ihmisen taudeille
GB9915200D0 (en) 1999-06-29 1999-09-01 Janssen Pharmaceutica Nv Neurotrophic factor receptor

Also Published As

Publication number Publication date
DE60026569T2 (de) 2007-02-08
DE60026569D1 (de) 2006-05-04
US7488588B1 (en) 2009-02-10
CA2397705A1 (en) 2001-08-30
JP2003523762A (ja) 2003-08-12
EP1257581B1 (de) 2006-03-08
AU782897B2 (en) 2005-09-08
AU1527101A (en) 2001-09-03
EP1257581A1 (de) 2002-11-20
WO2001062795A1 (en) 2001-08-30
FI20000394A0 (fi) 2000-02-21

Similar Documents

Publication Publication Date Title
BR9710665A (pt) Compostos que promovem o desenvolvimento do tecido
AR008588A1 (es) Molecula de acido nucleico aislada que hibridiza con un gen de saliva de pulga, proteina aislada codificada por dicha molecula, composicion terapeuticapara tratar la dermatitis alergica, kit de ensayo para determinar dicha dermatitis, molecula, virus y celula recombinantes, y anticuerpo aislado
WO2001055364A8 (en) Nucleic acids, proteins, and antibodies
DE69434292D1 (de) Für adseverin kodierendes gen
DE69732631D1 (de) Metabotropische gaba(b) rezeptoren, rezeptoren-spezifische liganden und deren anwendungen
ATE378408T1 (de) Transformierender wachstumsfaktor beta-9 (ztgfss9) aus säugetieren
WO2001055326A8 (en) Nucleic acids, proteins, and antibodies
FI930626A0 (fi) Proteinstruktur hos vaexttoxingelonin
ATE319743T1 (de) Zusammensetzungen auf der basis von gfr-alpha-4 und deren anwendungen
ATE286123T1 (de) Klonierung von pheromon rezeptoren aus vertebraten und deren verwendungen
WO2001055168A8 (en) Nucleic acids, proteins and antibodies
ATE336508T1 (de) Kaliumkanalprotein kcnq5, ein ziel für erkrankungen des zentralen nervensystems und herz-gefäss-systems
ATE511644T1 (de) Neues screening-verfahren
FI954889A7 (fi) Proteiini, jolla on TPO-aktiviteetti
SE9804274D0 (sv) Novel receptor
WO2001055167A8 (en) Nucleic acids, proteins, and antibodies
WO2001055449A8 (en) Nucleic acids, proteins, and antibodies
WO2001055162A8 (en) Nucleic acids, proteins, and antibodies
WO2001055305A3 (en) Nucleic acids, proteins, and antibodies

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties